Outcomes following implantation of the XXXX -eluting BioMatrix coronary stent: Primary analysis of the e-BioMatrix registry.

@entity1 @entity1187 @entity6 @entity548 @entity41976 @entity3446 @entity299 @entity583 @entity204 @entity715
OBJECTIVES: To assess the safety and efficacy of @entity41976 -eluting stents (BES, BioMatrix    and BioMatrix Flex   ) in routine clinical practice. BACKGROUND: The LEADERS randomized trial has documented equivalent efficacy and superior safety of the BES when compared to a first generation @entity3446 -eluting Cypher(TM) stent. METHODS: 5,472 @entity1 from 57 centers, treated with BES, were enrolled in an international multicenter registry and followed clinically up to 2 years. RESULTS: Mean @entity1 age was 63.2        11 years, 24% of @entity1 had @entity6 , and 49.8% presented with an @entity1187 . 99.3% of @entity1 were discharged on dual antiplatelet therapy (DAPT), 83.3% remained on DAPT at 1 year and 30.6% at 2 years. The incidence of the composite primary end point [major adverse @entity299 (MACE) at 12 months] was 4.5% [ @entity204 0.9%, @entity583 1.7%, clinically indicated target vessel revascularization (ci-TVR) 2.8%]. MACE incidence was 6.8% at 24 months ( @entity204 .5%, @entity583 2.4%, ci-TVR 4.3%). At 12 months, 32 @entity1 (0.6%) had suffered at least one definite or probable stent @entity715 (ST), and 91 @entity1 (1.7%) a @entity548 ( @entity548 ). Nine @entity1 with ST (27.3%) and 7 @entity1 with a @entity548 (7.7%) died during the first year after the index procedure. Between 12 and 24 months after implantation, there were 18 (0.4%) additional @entity548 and 8 (0.2%) additional ST. CONCLUSIONS: This large international cohort documents a low 12 and 24 months MACE incidence and a very low ST incidence in an unselected @entity1 population undergoing BES implantation. The results are in keeping with those of the randomized controlled LEADERS trial. Even though ST with this stent was a rare event, it was still associated with significant mortality. @entity548 remains a problem, and warrants improved tailoring of DAPT in recipients of drug eluting stents.    2015 Wiley Periodicals, Inc.
